Scientific Symposium Poster Presentations
October 2003, Houston, Texas
Carcinogenesis
Aplasia and Bone Marrow Transplantation
Protein Function: DNA Damage and Repair
Gene Therapy
Cell Signaling
Miscellaneous

Researchers discuss posters at the 2003 Scientific Symposium in Houston

Carcinogenesis

Blanche Alter, MD, MPH

National Cancer Institute, Rockville, Maryland

Cancer Epidemiology in Fanconi’s Anemia: Lessons from the IBMFS

Najim Ameziane, MSc

Vrije Universiteit Medical Center, Amsterdam, The Netherlands

Bi-allelic Silencing of the Fanconi Anemia Gene FANCF in an AML Cell

Chris Mathew, PhD

King’s College, London, UK

Haplo-Insufficiency of Fanconi Anaemia Gene LOCI in Cancer

Philip Rosenberg, PhD

National Cancer Institute, Rockville, Maryland

Risk of Squamous Cell Cancer (SCC) and Death in Transplanted and Untransplanted Patients with Fanconi Anemia

Bhuvanesh Singh, MD

Memorial Sloan-Kettering Cancer Center, New York

Molecular Classification of Fanconi Anemia-Associated Head and Neck Squamous Cell Carcinoma (HNSCC) Using Oligonucleotide Microarrays

Aplasia and Bone Marrow Transplantation

Farid Boulad, MD

Memorial Sloan-Kettering Cancer Center, New York

Fanconi Anemia: A Case Report of an Unusual Course

Farid Boulad, MD

Memorial Sloan-Kettering Cancer Center, New York

Secondary Hematopoietic Stem Cell Transplant for Acute Myelogenous Leukemia and Fanconi Anemia Following Cytoreduction with Busulfan, Fludarabine

Nupur Gangopadhyay, DVM, PhD

University of Pittsburgh Cancer Institute, Pennsylvania

Facilitation of Allogenic Bone Marrow Derived Stem Cell Engraftment Utilizing

Yigal Dror, MD

Hospital for Sick Children, Toronto, Canada

The Inherited Marrow Failure Syndromes: Epidemiology and Hematological Abnormalities at Presentation. Reports from the Canadian Inherited Marrow Failure Registry (CIMFR)

Jean-Hugues Dalle, MD

Hôpital Sainte-Justine, Montreal, Canada

Successful Pregnancies After Bone Marrow Transplantation in a Fanconi Anemia Patient

Jerome Larghero, PhD

Hôpital Sainte-Louis, Paris, France

Stem Cell Clonogenic Capacity in FA Patients is Linked to Somatic Mosaicism

John Wagner, MD

University of Minnesota, Minneapolis, Minnesota

Clinical Impact of Hematopoietic Cell Somatic Mosaicism

Menachem Bitan, MD

Hadassah Hebrew University Hospital, Jerusalem, Israel

The Use of Fludarabine Based Reduced Intensity Conditioning for the Treatment of Patients with Fanconi’s Anemia

Pooneh Heydari, MD

Tehran University of Medical Science, Tehran, Iran

Allogeneic Blood and Marrow Transplantation in Fanconi Anemia: an Experience of Iran

Protein Function: DNA Damage and Repair

Miriam Ferrer, MSc

Vrije University Medical Center, Amsterdam, The Netherlands

Nuclear-Cytoplasmic Shuttling of FANCA: Characterization of Three Novel Nuclear Export Sequences in FANCA

Celine Jacquemont, PhD Student

Institute Curie, Paris, France

Global Cellular Response to Specific DNA Damages of BRCA and FANC Mutated Cells

Nigel Jones, PhD

University of Liverpool, UK

Characterization of FANCG, BRCA2/FANCD1 and RAD51C Protein Interactions Using Chinese Hamster Cell Mutants

Satoru Komaki, MD

Oregon Health and Science University, Portland, Oregon

S-Phase Specific Hyper-Recombination Phenotype in Fanconi Anemia Cells

Muriel Lambert, PhD

New Jersey Medical School, Newark, New Jersey

FANCA and FANCG Interact Directly with Nonerythroid Alpha Spectrin II

Stephen Meyn, MD, FRCP(C)

Hospital for Sick Children, Toronto, Ontario, Canada

FANCD2 Associates with BLM at Telomeres in ALT-Immortalized Human Cells

Dora Papadopoulo, PhD

Institute Curie, Paris, France

Mutations in FANC and BRCA Genes Compromise the Faithful Rejoining of Broken DNA Ends

Jordi Surrallés, PhD

Universitat Autónoma de Barcelona, Bellaterra, Spain

No Role of the Fanconi Anaemia Gene FANCD2 in Normal Length Trinucleotide Repeat Instability

Andrei Thomashevski, PhD

University of Virginia, Charlottesville, Virginia

FA Core Complex Exists in 4 Distinct Forms in Different Subcellular Compartments

Weidong Wang, PhD

National Institute on Aging, National Institutes of Health, Baltimore, Maryland

Characterizing a Fanconi Anemia Core Complex

Margaret Zdzienicka, PhD

Leiden University Medical Center, Leiden, The Netherlands

Dissecting of the Cellular Responses to Cross-Linking Agents by Using Mammalian Mutants Sensitive to these Agents

Mark Brenneman, PhD

Rutgers University, Piscataway, New Jersey

BRCA2 (FANC-D1/B) Participates in Homologous Recombinational Repair via Multiple Protein- and DNA-Interacting Domains

Gene Therapy

Francesco Galimi, MD, PhD

The Salk Institute, La Jolla, California

Lentiviral-Mediated Gene Correction of Human Hematopoietic Progenitors from Fanconi Anemia Patients

Peter Kurre, MD

Fred Hutchinson Cancer Research Center, Seattle, Washington

Phenotypic Correction of Murine FANCC Deficient Hematopoietic Cells Using Foamy Virus Vectors

Anuj Mankad, Graduate Student

Oregon Health and Science University, Portland, Oregon

Natural “Embryonic Gene Therapy”: Acquired Secondary Mutation in Monozygotic Twin Sisters with Mutation in FANCA Gives Rise to Corrected Hematopoietic Lineage of Both Sisters

Meenakshi Noll, PhD

Oregon Health and Science University, Portland, Oregon

In Vivo Hematopoietic Stem Cell Selection using Clinically Relevant Drugs in Mouse Model of Fanconi Anemia Group A

Kaoru Yamada, PhD

Mt. Sinai School of Medicine, New York, New York

Retroviral Integration Site Analysis of Fanconi Anemia Patient Samples Following Retroviral-Mediated Gene Transfer

Cell Signaling

Kathryn Leung, MD

Baylor College of Medicine, Houston, Texas

Fanconi Anemia and Oxidative Stress:  The FANCG Protein Interacts with Peroxiredoxin 3

Johnson Liu, MD

Mount Sinai School of Medicine, New York, New York

Fanconi Anemia and Phosphoinositide (PI) / Inositol Phosphate (IP) Signaling Proteins

Filippo Rosselli, PhD

Institut Gustave Roussy, Villejuif, France

TNF-a Overproduction in Fanconi Anemia: Molecular Origins and Consequences

Linda Sandercock, PhD

University of Calgary, Canada

Sensitivity of Murine Fancc-/- Hematopoietic Cells to Nitric Oxide Extends to Human FANCC-/- Lymphoblasts

Robert Tebbs, PhD

Lawrence Livermore National Laboratory, Livermore, California

G2 Phase Delay in Hamster CHO FancG Knockout Cells

Giovanni Pagano, ScD

Italian National Cancer Institute, Mercogliano, Italy

Redox Toxicity Mechanisms Characterize All Xenobiotics Involved in Excess Toxicity to FA Cells

Miscellaneous

Jun Mi, PhD

University of Virginia, Charlottesville, Virginia

FANCG Phosphorylation at Serines 7, 383, and 387

W. Clark Lambert, MD, PhD

New Jersey Medical School, Newark, New Jersey

Correction of the Fanconi Anemia Phenotype at the Cellular Level Using Hydroxyurea: Implications for Etiopathogenesis and Management

Johannes Rischewski, MD

University Hospital Eppendorf, Hamburg, Germany

Mutation Spectrum of FANCC in Europe and DHLPC-Based Identification of a Large Deletion

Akiko Shimamura, MD, PHD

Dana-Farber Cancer Institute, Boston, Massachusetts

Mutational Analysis of the Fanconi Anemia Complementation Group D2 Gene, FANCD2

Jean Soulier, MD, PhD

Hôpital Saint-Louis, Paris, France

Analysis of the FANCD2 Pathway in FA Patients: New Diagnosis Tool, Detection of Mosaicism and Subtyping

Stacie Stone, Graduate Student

Oregon Health and Science University, Portland, Oregon

The Fanconi Anemia Pathway is Functionally Conserved in Xenopus

Elsa Callén Moréu, PhD Student

Universitat Autònoma de Barcelona, Spain

Genetic Characterization of Fanconi Anemia in Spanish Gypsies: the Ethnical Group with the Highest Incidence of Fanconi Anemia in the World

Henri van de Vrugt, PhD

Vrije Universiteit, Amsterdam, The Netherlands

Characterization of Murine Fancf

Michael Wallisch, PhD

Oregon Health and Science University, Portland, Oregon

FANCA is Spatially and Temporally Regulated During the Cell Cycle

Fanconi Anemia Research Fund, Inc. Fanconi Anemia Research Fund, Inc.